T1	Premise 645 789	There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.
T2	Premise 790 946	Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia.
T3	Premise 947 1082	At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning.
T4	Premise 1083 1281	Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group.
T5	Claim 1282 1437	At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET.
T6	Claim 1447 1570	after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life.
R1	Support Arg1:T3 Arg2:T6	
R2	Support Arg1:T1 Arg2:T5	
R3	Support Arg1:T2 Arg2:T5	
R4	Support Arg1:T4 Arg2:T6	
